Fractyl Health Inc
NASDAQ:GUTS
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
F
|
Fractyl Health Inc
NASDAQ:GUTS
|
66.1m USD |
Loading...
|
|
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
236.5B USD |
Loading...
|
|
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR |
Loading...
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD |
Loading...
|
|
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
105.6B ZAR |
Loading...
|
|
| US |
|
Schlumberger NV
NYSE:SLB
|
77B USD |
Loading...
|
|
| US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
64.2B USD |
Loading...
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
48.6B USD |
Loading...
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
34.4B CHF |
Loading...
|
|
| US |
|
Symbotic Inc
NASDAQ:SYM
|
33.8B USD |
Loading...
|
|
| ID |
|
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
530.4T IDR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Fractyl Health Inc
Glance View
Fractyl Health Inc is a US-based company operating in industry. The company is headquartered in Lexington, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2024-02-02. Fractyl Health, Inc. is a metabolic therapeutics company. The firm is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company’s lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The firm is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. The company is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Fractyl Health Inc is 100%, which is above its 3-year median of 48.3%.
Over the last 2 years, Fractyl Health Inc’s Gross Margin has increased from 35.1% to 100%. During this period, it reached a low of 33.6% on Sep 30, 2023 and a high of 100% on Oct 30, 2025.
